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Introduction: The predictors of long-term antipsychotic polypharmacy (APP) initiation are poorly understood.
Existing research has been hampered by residual confounding, failure to exclude cross-titration, and difﬁculties
in separating the timing of predictors and APP administration.
Materials and methods: Using data from the South London and Maudsley (SLaM) case register, we identiﬁed all
adult patients with serious mental illness (SMI) who were receiving care between 1st July 2011 and 30th June
2012. Exposures measured between 1st July and 31st December 2011 included socio-demographic, socioeco-
nomic, clinical and service use characteristics. We then determined if long-term APP (six or more months) had
been initiated between 1st January and 30th June 2012. Multivariable logistic regression models, adjusted for
socio-demographic and socioeconomic factors, were built to investigate the associations between the above fac-
tors and the initiation of long-term APP.
Results: We identiﬁed 6857 adults with SMI receiving SLaM care, of whom 115 (1.7%) were newly prescribed
long-term APP. In the adjusted models, predictors of long-term APP initiation included: symptoms (severity of
hallucinations and/or delusions), previous treatments (clozapine and long-acting injectable antipsychotic
agents), service use (more contact with outpatient services, community treatment order receipt), social factors
(higher area-level deprivation, homelessness) and socio-demographic status (younger age, not in a relationship).
Conclusion:Ourﬁndings highlight that certain patient groups are at an increased risk for long-termAPP initiation.
Identifying these groups earlier in their treatment could encourage clinicians to employ a broader range of inter-
ventions in addition to pharmacotherapy to reduce the risk of APP prescribing.
© 2016 Published by Elsevier B.V.
Keywords:
Antipsychotic polypharmacy
Predictors
Service use
Clinical symptoms
Socio-demographic
Socioeconomic
1. Introduction
Antipsychotic polypharmacy (APP; the concomitant administration
of two or more antipsychotics) remains common practice in treatment
of serious mental illnesses (SMI). Its prevalence is estimated to vary be-
tween 10 and 30% (Freudenreich and Goff, 2002; Gallego et al., 2012),
despite current guidelines recommending against APP use, except dur-
ing clozapine augmentation (APA, 2004; Lochmann van Bennekom
et al., 2013; NICE and NCCMH, 2013), and evidence of associations
with increased mortality (Ganguly et al., 2004; Joukama et al., 2006;
Waddington et al., 1998) and physical health problems (includingmet-
abolic and cardiovascular disorders) (Ganguly et al., 2004; Raedler,
2010). Examining factors that may predict APP prescribing is key to un-
derstanding its continued use.
To date, male gender (Ganguly et al., 2004; Kreyenbuhl et al., 2007a,
2007b; Morrato et al., 2007; Suokas et al., 2012), and younger age
(Kreyenbuhl et al., 2007a, 2007b; Morrato et al., 2007; Suokas et al.,
2012) have been found to be associated with APP, but there has been
a lack of information on socioeconomic factors (Barbui et al., 2006).
APP has been found to be associated with more frequent previous hos-
pital admissions (Faries et al., 2005; Ganguly et al., 2004; Kreyenbuhl
et al., 2007a, 2007b; Morrato et al., 2007), longer duration of previous
admissions (Suokas et al., 2012), higher number of previous outpatient
contacts (Ganguly et al., 2004; Kreyenbuhl et al., 2007a, 2007b) andpre-
vious antipsychotic medication use (Barbui et al., 2006; Ganguly et al.,
2004). Findings regarding the role of clinical symptoms in APP prescrib-
ing have been inconsistent (Barbui et al., 2006; Biancosino et al., 2005;
Centorrino et al., 2005).
Previous research has examined APP of varying duration (Broekema
et al., 2007; Clark et al., 2002; Faries et al., 2005; Ganguly et al., 2004; Ito
et al., 2005; Jaffe and Levine, 2003; Janssen et al., 2005; Misawa et al.,
2011; Sim et al., 2004; Suokas et al., 2012; Taylor et al., 2002) and has
often included polypharmacy during cross-titration, which has
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hampered deﬁnitive conclusions on predictors. More recently research
has begun to investigate APP with longer duration (N60 days) in an at-
tempt to distinguish between cross-titration and long-term treatment
(Barbui et al., 2006; Faries et al., 2005; Ganguly et al., 2004; Kadra
et al., 2015; Kreyenbuhl et al., 2007a, 2007b;Morrato et al., 2007). How-
ever, cross-titration is a process that can take up to 10 weeks to com-
plete (Correll et al., 2011; Lochmann van Bennekom et al., 2013);
therefore studies examining APP with a duration of 70 days or less can-
not deﬁnitively exclude switching. Aside fromheterogeneity in APP def-
inition, investigations to date have risked residual confounding due to
limited covariates in models (Centorrino et al., 2004; Faries et al.,
2005). Furthermore, limitations in being able to distinguish temporally
between the occurrence of APP prescribing and associated factors,
makes it difﬁcult to determine if the latter are predictors or conse-
quences (Kreyenbuhl et al., 2007a, 2007b). Another limitation include
small homogenous inpatient samples (Centorrino et al., 2004, 2005),
restricting generalisability.
Using data derived from a large de-identiﬁed electronic health re-
cords case register with near-universal coverage of a deﬁned popula-
tion, we investigated socio-demographic, socioeconomic, clinical, and
service-use predictors of long-term APP initiation in SMI.
2. Materials and methods
2.1. Study design, data source and study sample
This was a retrospective cohort studywithin a comprehensive regis-
ter of patients treated with SMI in the South London and Maudsley
(SLaM) NHS Foundation Trust. SLaM is one of the largest secondary
mental health care providers in Europe, serving four London boroughs
(Lambeth, Southwark, Lewisham and Croydon) and around 1.2M resi-
dents. As part of the National Health Service, SLaM is the universal pro-
vider of mental health services to this population. The Clinical Record
Interactive Search (CRIS) was developed in 2008 and enables re-
searchers to search and retrieve de-identiﬁed electronic health records
(EHRs) information for over 250,000 service users in SLaM. The CRIS
system has been described in detail (Perera et al., 2016; Stewart et al.,
2009) and is approved by the Oxfordshire Research Ethics Committee
C (reference 08/H606/71+5) as a database for secondary analysis.
Using CRIS, we ascertained all adult patients with a diagnosis of
schizophrenia (ICD-10 code: F20.x), schizoaffective disorder (F25.x) or
bipolar disorder (F31.x) andwhowere in contactwith SLaMclinical ser-
vices between 1st July 2011 and 30th June 2012. All potential predictors
were measured prior to 1st January 2012. APP initiation was deter-
mined for the period between 1st January and 30th June 2012, also re-
ferred to as the follow-up period.
2.2. Outcome measures
The primary outcome was long-term antipsychotic polypharmacy
(APP) initiation, deﬁned as the concomitant prescription of two or
more antipsychotic agents for at least six months, with the aim of
minimising the likelihood of cross-titration. All service users who com-
menced APP at some point from 1st January to 30th June 2012, but who
had not received APP in the 6 months prior to this were considered to
have been ‘initiated’ on long termAPP. A detailed account of themethod
used for APP ascertaining in CRIS and the validation of this technique
have been described elsewhere (Kadra et al., 2015).
2.3. Explanatory variables
Agewas calculated on the 1st January 2012 and categorised by quar-
tiles. The remaining socio-demographic and socioeconomic factors
were derived from the last entry recorded prior to 1st January 2012.
Seventeen ethnic group categories were collapsed into “White”, “Black
Caribbean”, “Black African” and “Other”, due to small numbers in
some cells. Relationship statuswas deﬁned as “in a current relationship”
(cohabitating, married or civil partnership) and “not in a relationship”
(single, divorced, separated, widowed, unknown). Employment status
was recorded as being in “paid employment” (part-time, full-time,
self-employed) and “not in paid employment” (unemployed, registered
disabled, retired, student, looking after children, volunteer, in training,
not known, other). We used an area-level index of multiple deprivation
to estimate socioeconomic status based on seven domains of depriva-
tion ascertained from 2007 UK Census estimates (employment, income,
education, health, barriers to housing and services, crime, and living en-
vironment), which areweighted and combined into an overall score ap-
plied to a given geographic area (DCLG, 2011). In this case, multiple
deprivation indices were applied to lower super output areas (LSOAs),
which are the smallest enumeration unit, each containing on average
1500 residents (DCLG, 2011). LSOAs were categorised in tertiles based
on the four catchment boroughs. In addition, homelessness (Noble
et al., 2008) was ascertained based on ‘no ﬁxed abode’ codes.
Clinical symptom presence/severity was estimated from the most
recent Health of the Nation Outcome Scale (HoNOS) completed prior
to 1st January 2012. HoNOS is a clinical outcome instrument in wide
routine use, composed of 12 items designed to measure behaviour, im-
pairment, symptoms, and social functioning (Wing et al., 1998). Items
are scored on a scale of 0 (no problem) to 4 (severe to very severe prob-
lem). Due to small cell sizes, subscale scores were collapsed into three
categories: 0 “not a problem”; 1 “minor problem requiring no action”;
2–4 “signiﬁcant problem” (Hayes et al., 2012). Items that provided over-
lapping information to other variables used in this analyses were re-
moved; therefore we did not include item 9 (assessing relationship
problems), item 11 (assessing living conditions) and item 12 (assessing
occupational problems). Item 8 (assessing other mental health prob-
lems) was also excluded, as the following comorbid diagnoses were
ascertained using information available from free-text and structured
ﬁelds: i) depression [having received a diagnosis of depression (ICD-
10: F32, F33) and/or scoring ‘mild’ to ‘signiﬁcant’ on HoNOS item 7];
ii) substance use [having received a diagnosis of substance use disorder
(ICD-10: F10–16) and/or scoring ‘mild’ to ‘signiﬁcant’ on HoNOS item
3]; and iii) personality disorder [having received a diagnosis of person-
ality disorder (ICD-10: F60; F61)].
We considered six measures of service use: i) previous outpatient
contact was determined through the proportion of days each person
had received face-to-face contact as an outpatient between 1st July
and 31st December 2011 (multiple events on a single daywere counted
as one day of clinical contact, whilst clinical contact with outpatient ser-
vices during an inpatient admissionwas not counted); ii) the number of
days spent as an in-patient between 1st July and 31st December 2011
were determined separately; iii) we identiﬁed the number of previous
antipsychotics used in the six months prior to follow-up; iv) we identi-
ﬁed all patients who had received a community treatment order (CTO)
prior to the start of follow-up [CTOs refer to a conditional discharge
from inpatient admission, commonly implemented for a period of six
months to improve adherence to medication and promote regular con-
tact with services (DoH, 2007)]; dichotomous variables were generated
to indicate whether, since 2007, patients v) had ever used clozapine or
vi) ever used a long acting injectable (LAI) antipsychotic agent.
2.4. Statistical analysis
STATA 12 was used to conduct all statistical analyses. We estimated
APP prevalence and incidence of newly initiated long-term APP in a six-
month window. Further analyses focused on predictors of long-term
polypharmacy initiation. Multivariable models included potential con-
founders such as age, gender, ethnicity, relationship status, employ-
ment, and deprivation status. Clinical and service use factors were not
included as covariates due to possible over-adjustment for potential
causal pathway factors.
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Several sensitivity analyses were carried out. Firstly, we tested
whether the timing of the HoNOS assessment had an effect on the asso-
ciation between clinical items and APP initiation, by restricting the
analyses to HoNOS scores obtained within the last year prior to the
start of follow-up. We further tested whether being a local resident
(as opposed to patients referred from the wider national catchment
Table 1
Cohort characteristics.
Variables Total cohort
N (%)
APPa
N (%)
APP initiationa
N (%)
Total sample 6857 331 (4.8) 115 (1.7)
Socio-demographic and socioeconomic factors
Age
16–35 1737 (25.3) 117 (35.3) 45 (39.1)
36–45 1789 (26.1) 105 (31.7) 31 (27.0)
46–55 1678 (24.5) 77 (23.3) 22 (19.1)
56+ 1653 (24.1) 32 (9.7) 17 (14.8)
Gender
Female 2821 (41.1) 111 (33.5) 40 (34.8)
Male 4036 (58.9) 220 (66.5) 75 (65.2)
Ethnicity group
White 3124 (45.6) 125 (37.8) 41 (35.7)
Black Caribbean 992 (14.5) 54 (16.3) 16 (13.9)
Black African 1851 (26.9) 106 (32.0) 43 (37.4)
Other 890 (13.0) 46 (13.9) 15 (13.0)
Relationship status
Not in a relationship 6052 (88.3) 311 (94.0) 111 (96.5)
In relationship 805 (11.7) 20 (6.0) 4 (3.5)
Employment status
Not in paid employment 6521 (95.1) 326 (98.5) 113 (98.3)
In paid employment 336 (4.9) 5 (1.5) 2 (1.7)
Deprivation level in area of residence
Low level 2087 (32.7) 95 (30.2) 25 (22.5)
Medium level 2111 (33.1) 113 (35.9) 40 (36.1)
High level 2107 (33.0) 97 (30.8) 42 (37.8)
Homelessness 74 (1.2) 10 (3.1) 4 (3.6)
Clinical factors
Comorbid diagnosis
Depression 3437 (50.1) 165 (49.9) 50 (43.5)
Personality disorder 895 (13.1) 63 (19.0) 20 (17.4)
Substance use 1956 (28.5) 103 (31.1) 38 (33.0)
Overactive and aggressive behaviour
Not a problem 4127 (64.9) 198 (62.3) 64 (59.3)
Minor problem 1333 (21.0) 66 (20.8) 26 (24.0)
Signiﬁcant problem 898 (14.1) 54 (16.9) 18 (16.7)
Non-accidental self-injury
Not a problem 5850 (92.1) 292 (91.8) 100 (92.6)
Minor problem 326 (5.1) 20 (6.3) 5 (4.6)
Signiﬁcant problem 179 (2.8) 6 (1.9) 3 (2.8)
Cognitive problems
Not a problem 3799 (59.9) 181 (57.3) 64 (59.8)
Minor problem 1578 (24.9) 83 (26.3) 23 (21.5)
Signiﬁcant problem 966 (15.2) 52 (16.4) 20 (18.7)
Physical illness or disability
Not a problem 3502 (55.2) 175 (55.0) 57 (52.8)
Minor problem 1254 (19.8) 73 (23.0) 23 (21.3)
Signiﬁcant problem 1591 (25.0) 70 (22.0) 28 (25.9)
Hallucinations and delusions
Not a problem 2688 (42.3) 97 (30.5) 34 (31.5)
Minor problem 1314 (20.7) 74 (23.3) 25 (23.1)
Signiﬁcant problem 2348 (37.0) 147 (46.2) 49 (45.4)
Problems with activities of daily living
Not a problem 2842 (44.8) 121 (38.2) 44 (41.1)
Minor problem 1572 (24.8) 86 (27.1) 28 (26.2)
Signiﬁcant problem 1934 (30.4) 110 (34.7) 35 (32.7)
Service use
Days of inpatients stay in previous six months, mean± SD (range) 11.8 ± 36.3 (0–184) 35.8 ± 60.0 (0–184) 18.8 ± 44.2 (0–184)
Days of outpatient contact in previous six months, mean ± SD (range) 9.4 ± 13.9 (0–174) 12.5 ± 15.1 (0–153) 12.2 ± 20.1 (0–153)
Previous CTOs
No 6483 (94.6) 394 (88.8) 98 (85.2)
Yes 374 (5.4) 37 (11.2) 17 (14.8)
Number of antipsychotics used in the previous six months, mean ± SD (range) 1.0 ± 1.0 (0–8) 2.2 ± 1.2 (0–7) 1.2 ± 1.0 (0–6)
Previous clozapine use
No 5643 (82.3) 151 (45.6) 80 (69.6)
Yes 1214 (17.7) 180 (54.4) 35 (30.4)
Previous LAI use
No 4405 (64.2) 167 (50.5) 52 (45.2)
Yes 2452 (35.8) 164 (49.5) 63 (54.8)
a Antipsychotic polypharmacy (APP) lasting for six or more months.
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area) had aneffect on the association betweenAPP and all exposure var-
iables. Patients resident outside the local catchment area can be referred
to SLaM services for specialist treatment, due to particularly severe or
treatment-resistant symptoms. Therefore, this group could be inher-
ently different to local patients.
3. Results
We identiﬁed 7201 adults with a SMI diagnosis who were receiving
SLaM care between January and June 2012.We excluded 344 patients as
they were not receiving care in SLaM services in the six months prior to
1st January 2012, resulting in a total sample size of 6857 patients. We
found that 331 (4.8%) patients were receiving antipsychotic
polypharmacy for six or more months between 1st January and 30th
June 2012 (this sample is also referred to as overall APP) and 115
(1.7%) were newly initiated on long-term APP. Table 1 summarises the
characteristics for the total cohort and by overall and newly prescribed
APP.
Table 2 describes the prevalence of ﬁrst (FGA) and second-
generation antipsychotics (SGA) that were prescribed as part of APP.
Two or more SGAs were most commonly co-prescribed. Of the newly
initiated sample, 24.3% were receiving clozapine APP.
Table 3 summarises results from the unadjusted and adjusted logis-
tic regression models, which examine the potential socio-demographic
and socioeconomic predictors of newly prescribed APP. In the fully ad-
justed model, individuals in early adulthood (aged 16–35) were more
likely to be initiated on APP than older adults (aged 56+) (OR 2.1,
95% CI 1.1–3.7, p = 0.016), whereas being in a relationship was associ-
ated with a reduced risk for APP initiation (OR 0.3, 0.1–0.9, p = 0.043).
Experiencing a high level of deprivation and more speciﬁcally being
homelesswas also associatedwith an increased risk for being newly ini-
tiated on long-term APP (OR 3.3, 1.1–9.9, p = 0031).
As described in Table 4, overall clinical symptoms, as measured by
HoNOS administered closest to the start of follow-up, were not predic-
tive of APP initiation, with the exception of signiﬁcant problems with
hallucinations and/or delusions (OR 1.6, 1.0–2.5, p = 0.048). In a sensi-
tivity analysis, where the investigation was restricted to HoNOS scores
obtained within the last year prior to the observation period, this asso-
ciation was not substantially changed in strength, although fell outside
statistical signiﬁcance (OR 1.5, 0.9–2.4, p = 0.146).
Table 5 summarises associations between newly prescribed APP and
service use. We found that the risk of APP initiation increased with
every additional day of outpatient contact (OR 1.0099, 1.0002–1.0197,
p = 0.045) received in the previous six months, even after adjusting
for possible confounders. Similarly, having previously received a CTO
(OR 2.6, 1.5–4.5, p b 0.001), previous use of clozapine (OR 1.8, 1.2–2.7,
p=0.006), and previous LAI use (OR 2.2, 1.5–3.2, p b 0.001)were all as-
sociatedwith increased risk of being newly prescribed long-termAPP in
the fully adjusted models.
In total, 419 (6.7%) patients in the sample had been referred for
SLAM services from other boroughs rather than being catchment area
residents. A sensitivity analysis indicated that after restricting the
analyses to patients residing in the SLaMcatchment area, themagnitude
and direction of ORs were similar for all associations; however some
were no longer signiﬁcant including being in a relationship (p =
0.056), having problems with hallucinations and/or delusions (p =
0.123) and outpatient contact in the previous 6 months (p = 0.058).
Also, after excluding patients from outside the catchment there were
no longer any homeless people prescribed long-term APP; therefore
an analysis of this variable was not possible.
4. Discussion
Our results indicate that age, socioeconomic circumstances, psy-
chotic symptoms, prior outpatient contact, CTOs, prior clozapine and/
or LAI use are signiﬁcant, independent predictors of newly prescribed
long-term APP.
Our ﬁndings are in keepingwith existing research (Mace and Taylor,
2015) indicating that SLaM has a considerably lower prevalence of APP
in comparison to a UK national sample and other US studies
(Freudenreich and Goff, 2002; Gallego et al., 2012). Considering service
use measures, our results both conﬁrm previous research and generate
novel ﬁndings. For example, our results support previous research
which has indicated that prior service use, such asmore frequent outpa-
tient contact (Ganguly et al., 2004; Kreyenbuhl et al., 2007a, 2007b),
previous use of LAI, and clozapine (Ganguly et al., 2004), are associated
with an increased risk for longer term APP (i.e. N60 days). Importantly,
our ﬁndings further indicate that only a third of the patients initiated on
APP had previously been trialled on clozapine. This has been previously
suggested (Howes et al., 2012; Nielsen et al., 2012), and highlights that
prescribing guidelines (i.e. that APP should only be considered after tri-
als of two individual agents followed by clozapine) are not consistently
applied in ‘real world’ practice. Contrary to some previous reports, we
found no evidence to suggest that APP initiation is predicted by the
number of days spent as an inpatient or number of antipsychotics
used (Barbui et al., 2006; Ganguly et al., 2004; Morrato et al., 2007) in
the previous six months. An important issue to bear in mind is that
Table 2
Prevalence and distribution of long-term antipsychotic polypharmacy (APP).
Types of antipsychotic
polypharmacy
APP
(n = 331)
APP initiation
(n = 115)
n % (95% CI) n % (95% CI)
First generation antipsychotics
(FGA) only
9 2.7 (1.3–5.1) 6 5.2 (1.9–11.0)
Second generation antipsychotics
(SGA) only
216 65.3 (59.9–70.4) 62 53.9 (44.4–63.2)
FGA + SGA 106 32.0 (27.0–37.3) 47 40.9 (31.8–50.4)
APP inclusive of FGA or SGA LAIa 72 21.8 (17.3–26.2) 35 30.4 (21.9–38.9)
APP inclusive of clozapinea 165 49.9 (44.4–55.3) 28 24.3 (16.4–32.3)
a Categories overlap with APP by generation (FGA; SGA; FGA + SGA).
Table 3
Logistic regression analysis of socio-demographic and socioeconomic predictors of anti-
psychotic polypharmacy initiation.
Crude OR
(95% CI)
Adjusted ORa
(95% CI)
Adjusted
p-value
Age
16–35 2.6 (1.6–4.5) 2.1 (1.1–3.7) 0.016
36–45 1.7 (0.9–3.0) 1.4 (0.8–2.6) 0.291
46–55 1.3 (0.7–2.4) 1.1 (0.6–2.1) 0.749
56+ Reference Reference
Gender
Female Reference Reference
Male 1.3 (0.9–1.9) 1.1 (0.7–1.7) 0.621
Ethnicity group
White Reference Reference
Black Caribbean 1.2 (0.7–2.2) 1.1 (0.6–2.1) 0.691
Black African 1.8 (1.2–2.8) 1.4 (0.9–2.3) 0.129
Other 1.3 (0.7–2.3) 1.3 (0.7–2.4) 0.403
Relationship status
Not in a relationship Reference Reference
In relationship 0.3 (0.1–0.7) 0.3 (0.1–0.9) 0.043
Employment status
Not in paid employment Reference Reference
In paid employment 0.3 (0.1–1.4) 0.4 (0.1–1.6) 0.181
Deprivation level
Low level Reference Reference
Medium level 1.6 (0.9–2.6) 1.4 (0.9–2.4) 0.164
High level 1.7 (1.0–2.8) 1.5 (0.9–2.5) 0.116
Homelessness 4.7 (1.6–13.9) 3.3 (1.1–9.9) 0.031
Values in bold are statistically signiﬁcant (≤ 0.05).
a Models adjusted for all socio-demographic and socioeconomic factors.
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we speciﬁcally investigated APP initiation, while previous research has
rarely been able to account for pre-existing APP use and thus has not
been able to distinguish factors associated with its initiation from
those associated with its continuation. Furthermore, it is important to
consider service use predictors in the context of the service where
they are examined. For example, in the UK, there has been a nationwide
drive to reduce the number and duration of inpatient admissions.
Therefore, it is possible that factors, which would have previously war-
ranted an inpatient admission, are nowpossibly driving APP prescribing
due to limited beds. Future studies may beneﬁt from testing further
whether APP is initiated in the community in order to prevent hospital
admission. Our results further suggest that factors such as prior history
of CTOs (a proposed proxy for non-adherence) are associated with an
increased risk for long-term APP, something that has not been previ-
ously investigated (Biancosino et al., 2005; Patel et al., 2011).
Experiencing signiﬁcant hallucinations and/or delusions, as rated on
the respective HoNOS sub-scale, emerged as the sole symptomatic pre-
dictor of long-term APP initiation. This contrasts with some previous
studies, where no associations were found between general psychopa-
thology and long-term APP (Barbui et al., 2006); however, most studies
of smaller inpatient samples (Biancosino et al., 2005; Centorrino et al.,
2004, 2005) have indicated an association between APP and positive
symptoms. Lastly, despite some previous evidence indicating that co-
morbid diagnoses such as personality disorder (Ganguly et al., 2004)
and depression (Kreyenbuhl et al., 2007a, 2007b) are associated with
reduced likelihood of APP prescribing, we detected no such associations
with APP initiation.
Of the demographic factors that we examined, we found a positive
association between APP and younger age (Kreyenbuhl et al., 2007a,
2007b; Morrato et al., 2007; Suokas et al., 2012). There are several po-
tential explanations. For example, it is possible that younger patients
are seen as better able to tolerate side-effects associated with APP
(Alexopoulos et al., 2004; Shin et al., 2013) or that higher perceived
risk (e.g. of violence) inﬂuences prescribing behaviour. Ethnic back-
ground and gender, in contrast to other studies (Ganguly et al., 2004;
Kreyenbuhl et al., 2007a, 2007b; Suokas et al., 2012), were not signiﬁ-
cantly associated with APP. We found a potentially protective effect of
being in a relationship (Kreyenbuhl et al., 2007a, 2007b), which could
suggest that being able to sustain an intimate relationship may be
seen as a marker for better functioning and less impairment. Depriva-
tion level emerged as the sole socioeconomic factor that predicted initi-
ating long-term APP. In contrast with previous research where the
principal focus has been on employment status (Barbui et al., 2006),
our study suggests that deprivation is potentially a more meaningful
measure of socioeconomic status. It is possible that homelessness acts
as a proxy for illness severity (Gaebel and Zielasek, 2015); however,
this association is novel, and the role of socioeconomic features in gen-
eral warrants further investigation.
This study had several strengths. Measuring predictors prior to APP
initiation allowed us to separate the exposures and outcome, thereby
reducing the inﬂuence of reverse causality. We also examined APP of
at least six months duration, which is likely to have excluded cross-
titration, although it is possible that some instances may have begun
with this (i.e. where a cross-titration was commenced but not com-
pleted due to worsening symptoms, resulting in the observed APP).
We explored multiple factors simultaneously as predictors and con-
founders, and used data from a large sample including both inpatients
and outpatients. Finally, in common with most NHS Mental Health
Trusts in the UK, SLaM is close to being a monopoly mental healthcare
provider for its geographic catchment; therefore our sample is likely
to be representative of patients seen by secondary care (Stewart et al.,
2009).
Therewere several potential limitations. Despite adjusting formulti-
ple confounders, it is possible that some residual confoundingmay have
occurred.Wewere unable tomeasure factors such as duration of illness
or stages of treatment as patients entered the observation period. In ad-
dition, we were unable to measure clinician related factors such as pre-
scriber experience of initiating APP and knowledge of side-effects and
adverse outcomes (Correll and Gallego, 2012; Correll et al., 2011; Gee
et al., 2014). In contrast to previous researchwhere standardised symp-
tomatic assessments have been used (e.g. PANSS, BPRS), symptom as-
sessment in this study was limited to individual HoNOS items,
Table 4
Logistic regression analysis of clinical predictors of antipsychotic polypharmacy initiation.
Crude OR
(95%CI)
Adjusted ORa
(95% CI)
Adjusted
p-value
Comorbid diagnosis
Depression
No Reference Reference
Yes 0.8 (0.5–1.1) 0.8 (0.6–1.2) 0.286
Personality disorder
No Reference Reference
Yes 1.4 (0.9–2.3) 1.2 (0.7–2.0) 0.464
Substance use
No Reference Reference
Yes 1.2 (0.8–1.8) 1.0 (0.6–1.5) 0.873
Overactive and aggressive behaviour
Not a problem Reference Reference
Minor problem 1.3 (0.8–2.0) 1.3 (0.8–2.0) 0.331
Signiﬁcant problem 1.3 (0.8–2.2) 1.3 (0.8–2.2) 0.339
Non-accidental self-injury
Not a problem Reference Reference
Minor problem 0.9 (0.4–2.2) 0.9 (0.4–2.2) 0.804
Signiﬁcant problem 1.0 (0.3–3.1) 0.9 (0.3–3.0) 0.922
Cognitive problems
Not a problem Reference Reference
Minor problem 0.9 (0.5–1.4) 0.9 (0.6–1.5) 0.818
Signiﬁcant problem 1.2 (0.7–2.0) 1.4 (0.8–2.3) 0.222
Physical illness or disability
Not a problem Reference Reference
Minor problem 1.1 (0.7–1.8) 1.4 (0.9–2.4) 0.159
Signiﬁcant problem 1.1 (0.7–1.7) 1.6 (0.9–2.6) 0.064
Hallucinations and delusions
Not a problem Reference Reference
Minor problem 1.5 (0.9–2.5) 1.5 (0.9–2.5) 0.141
Signiﬁcant problem 1.7 (1.1–2.6) 1.6 (1.0–2.5) 0.048
Problems with activities of daily living
Not a problem Reference Reference
Minor problem 1.2 (0.7–1.9) 1.2 (0.7–1.9) 0.506
Signiﬁcant problem 1.2 (0.8–1.8) 1.2 (0.8–1.9) 0.414
Values in bold are statistically signiﬁcant (≤ 0.05).
a Models adjusted for all socio-demographic and socioeconomic factors.
Table 5
Logistic regression analysis of service use predictors of antipsychotic polypharmacy
initiation.
Crude OR
(95% CI)
Adjusted ORa
(95% CI)
Adjusted
p-value
Days of inpatients stay in
previous six months
1.0 (1.00–1.01) 1.0 (0.9–1.0) 0.309
Days of outpatient contact in
previous six months
1.0095
(1.0007–1.0183)
1.0099
(1.0002–1.0197)
0.045
Number of antipsychotics used in
the previous six months
1.2 (1.0–1.4) 1.1 (0.9–1.3) 0.291
Previous CTOs
No Reference Reference
Yes 3.1 (1.8–5.2) 2.6 (1.5–4.5) b0.001
Previous clozapine use
No Reference Reference
Yes 2.1 (1.4–3.1) 1.8 (1.2–2.7) 0.006
Previous LAI use
No Reference Reference
Yes 2.2 (1.5–3.2) 2.2 (1.5–3.2) b0.001
Values in bold are statistically signiﬁcant (≤ 0.05).
a Models adjusted for all socio-demographic and socioeconomic factors.
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measured at one point in time. This scale has received some previous
criticism with regards to its measurement of symptoms (Bebbington
et al., 1999; Stein, 1999), and we were only able to analyse a composite
measure of psychotic symptoms. It is possible that true associationsmay
have been concealed, and further research is required into the role of
observed and recorded symptomatology in clinical decision-making.
We believe that our ﬁndings have several important clinical implica-
tions. Long-term APP prescribing is unlikely to be predicted by a single
factor, rather it is precipitated by a complex interplay between patient
and wider environmental contexts, where clinical symptoms as well
as service use such as previous treatment and contact with services
may inﬂuence decision-making. Furthermore, our study highlights
that there are certain patient groups, such as patients whose symptoms
are resistant to treatment, that are at an increased risk for APP initiation.
Although a proportion of patients prescribed APP do receive pharmaco-
therapy that is in linewith current treatment guidelines (i.e. LAI and clo-
zapine trials that precede APP initiation), a subgroup is offered APP
sooner than recommended. Future research would beneﬁt from focus-
ing further on patients that are inappropriately initiated on APP, as a
long-term treatment plan. Identifying these groups could encourage cli-
nicians to employ a broader range of interventions, including earlier tri-
als of clozapine and/or alternative treatments to pharmacotherapy to
reduce the risk of APP prescribing.
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